Antipsychotics

A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.

A new study in the journal Translational Psychiatry, an influential journal in biological psychiatry published by Nature, challenges the state of the research on antipsychotic drugs.

In a study of an earlier randomized controlled trial of antipsychotics, researchers from Yale and the U.K found that second-generation antipsychotics were as likely...

The US Food and Drug Administration is warning the public that the antipsychotic medication ziprasidone "is associated with a rare but serious skin reaction...

A new study, published in the Journal of Clinical Psychiatry, investigates the effects of anticholinergic medications, such as antidepressants and antipsychotics, on cognition in older adults diagnosed with schizophrenia.

New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.

A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.

Long-term exposure to prolactin-increasing antipsychotics increases the odds of developing breast cancer.

No placebo controlled trials provide evidence of antipsychotics in first-episode psychosis.

The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...

Antipsychotics present a known risk for major side effects. A new study suggests that certain antipsychotics may present a greater risk for cardiovascular disease than others.

Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.

Evidence of duplicate publishing in articles analyzing data from clinical trials testing second-generation antipsychotics for depression

Researchers believe that side-effect monitoring is critical because of the increase in the use of antipsychotics

New research examines service user attitudes on discontinuing and reducing antipsychotic drugs.

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

Antipsychotics are currently the predominant treatment for individuals diagnosed with schizophrenia, but there is an accumulating body of research that links the use of these drugs to structural abnormalities in the brain. A recent meta-analysis suggests that gray matter loss in the brain may depend on the dose and class of the antipsychotic.

Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

A recently published study from noted critical psychiatry expert Joanna Moncrieff explored the barriers that prevent clinicians from helping service users in discontinuing or...

A partnership designed to decrease antipsychotic use in elderly patients may have led to increased use of medications with even worse risk/benefit profiles.

Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.

Nearly 90,000 American adults are going to emergency rooms every year in response to adverse events from psychiatric medications, according to a study in...

Large cohort study demonstrates that those with an intellectual disability are at an increased risk for movement disorder side effects of antipsychotics.